Predictors of Radiation Pneumonitis in Patients Receiving Intensity Modulated Radiation Therapy for Hodgkin and Non-Hodgkin Lymphoma
Chelsea C. Pinnix(The University of Texas MD Anderson Cancer Center), Bouthaina S. Dabaja, Maria Alma Rodriguez(The University of Texas MD Anderson Cancer Center), Jason R. Westin(The University of Texas MD Anderson Cancer Center), Luis Fayad(The University of Texas MD Anderson Cancer Center), Yago Nieto(The University of Texas MD Anderson Cancer Center), Francesco Turturro(The University of Texas MD Anderson Cancer Center), Yasuhiro Oki(The University of Texas MD Anderson Cancer Center), Loretta J. Nastoupil(The University of Texas MD Anderson Cancer Center), Sairah Ahmed(The University of Texas MD Anderson Cancer Center), Nathan Fowler(The University of Texas MD Anderson Cancer Center), Grace L. Smith(The University of Texas MD Anderson Cancer Center), Pamela K. Allen(The University of Texas MD Anderson Cancer Center), Mani Akhtari(The University of Texas MD Anderson Cancer Center), Michele A. Fanale(The University of Texas MD Anderson Cancer Center), Jay P. Reddy(The University of Texas MD Anderson Cancer Center), Jorge Romaguera(The University of Texas MD Anderson Cancer Center), Sarah A. Milgrom(The University of Texas MD Anderson Cancer Center), E.M. Osborne(The University of Texas MD Anderson Cancer Center), Valerie Reed(The University of Texas MD Anderson Cancer Center), Fredrick B. Hagemeister(The University of Texas MD Anderson Cancer Center), Isidora Arzu(The University of Texas MD Anderson Cancer Center), Christine F. Wogan(The University of Texas MD Anderson Cancer Center)
International Journal of Radiation Oncology*Biology*Physics
April 8, 2015
Cited by 132
Related Papers
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies
|Journal of Clinical Oncology|2012|1.1k
Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma
|Nature Medicine|2015|1.1k
Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium
|Journal of Clinical Oncology|2020|782